This content is machine translated Small cell lung carcinoma Durvalumab approved as first immunotherapy for patients with LS-SCLC Durvalumab has been approved as a monotherapy in Switzerland for the treatment of adult patients with unresectable small cell lung cancer (LS-SCLC, limited-stage small cell lung cancer) whose disease has...…
